Journal of Clinical Oncology
Articles in this Issue
Enlonstobart in patients with PD-L1 positive recurrent/metastatic cervical cancer: Updated survival results of the phase II study.
5522 Background: Enlonstobart is a PD-1 inhibitor that has demonstrated durable anti-tumor activity and acceptable safety in patients with PD-L1 positive...
ctDNA for disease detection and monitoring in head and neck cancer: A real-world study.
e18064 Background: Cell-free circulating tumor DNA (ctDNA)-based test has emerged as a promising tool in informing treatment modification in solid tumors....
The TIME trial: Phase II randomized controlled trial of time-of-day–specified immunotherapy for advanced melanoma.
TPS9601 Background: Ipilimumab + nivolumab is standard of care for advanced melanoma patients based on data from the CheckMate 067 trial. The recent 10-ye...
Assessing the impact of high body mass index on acute lymphoblastic leukemia: A 30-year global analysis.
e18536 Background: The global burden of diseases linked to modifiable risk factors is a critical focus of public health research. Among these, high body m...
Risk and predictors of late second primary malignancies in long-term breast, prostate, colon, and rectal cancer survivors.
1642 Background: In older, long-term (5-year) cancer survivors, mortality risks from aging and treatment-related effects may surpass those of their index...
Advance care planning documentation prior to end-of-life systemic therapy: A single institution retrospective review.
e24031 Background: Systemic anticancer therapy (SACT) at end-of-life (EOL) is associated with decreased quality of life and high healthcare use. Despite m...
An exploratory study of clostridium butyricum combined with neoadjuvant chemoimmunotherapy in urothelial carcinoma.
4585 Background: Neoadjuvant chemoimmunotherapy using gemcitabine, cisplatin, and anti-PD1 has shown survival benefits for advanced bladder cancer patient...
Outcomes of merkel cell carcinoma: A 10-year population-based study in Queensland, Australia.
e21593 Background: Queensland (QLD) has the highest incidence of Merkel Cell Carcinoma (MCC) within Australia, with a rate of 2.3/100,000 in 2021. This st...
myTRIAList reach and utilization: A novel digital cancer clinical trial finder and education platform.
e13504 Background: Despite longstanding efforts to increase cancer clinical trial (CCT) enrollment, informational and attitudinal barriers persist. While...
Trends in neuroendocrine tumor-related mortality, 1999–2020: A CDC WONDER database analysis.
e18155 Background: Every year, around 6 individuals per 100,000 population in the United States (US) are affected by neuroendocrine tumors (NETs). Althoug...
Impact of a digital health platform in improving PSA and blood pressure levels in members living with cancer and co-morbid hypertension in Nigeria: A retrospective analysis.
e13728 Background: Cancer and hypertension are major causes of significant morbidity and mortality, globally. More specifically, studies have reported tha...
Age acceleration among adolescent and young adult patients with Ewing sarcoma and osteosarcoma.
11051 Background: Ewing sarcoma (ES) and osteosarcoma (OS) are two common bone malignancies affecting adolescent and young adult (AYA) patients, often req...
A prospective, single-arm, phase II study to evaluate the efficacy and safety of perioperative tislelizumab in resectable non-small-cell lung cancer (NSCLC).
8049 Background: Perioperative immunotherapy has emerged as a promising strategy for the treatment of resectable non-small cell lung cancer (NSCLC). This...
Risk of gastric cancer among people with BRCA pathogenic gene variants: A systematic review and meta-analysis.
e16153 Background: Patients with BRCA pathogenic gene variants (PGVs) have an increased risk for breast, ovarian, pancreatic, and prostate cancer, with em...
AI-powered analysis of the tumor immune microenvironment in lung squamous cell carcinomas with and without neoadjuvant therapy.
e20017 Background: Chemotherapy (CT) and radiotherapy (RT) are known modulators of the local and systemic immune response with stimulating and inhibiting...
Development and validation of prediction models for 5-year and 10-year ipsilateral breast tumor recurrence after breast-conserving surgery.
575 Background: Ipsilateral breast tumor recurrence (IBTR) remains a critical concern for patients undergoing breast-conserving surgery (BCS). Reliable pr...
A phase 2 study of sirolimus in combination with metronomic chemotherapy (CHOAnome) in children with recurrent and/or refractory solid and CNS tumors.
10054 Background: Outcomes for recurrent and/or refractory (R/R) solid and central nervous system (CNS) tumors remain poor. Sirolimus, an mTOR inhibitor,...
Comparative survival outcomes among histological subtypes of non-small cell lung cancer in the United States.
e20072 Background: Non-small cell lung cancer (NSCLC) is the most common type of lung cancer. However, a comparative survival impact of its histological v...
Preclinical study of safety and efficacy in vivo of a yttrium-90 resin microspheres glue formulation in a large animal model of pancreatic cancer.
e16438 Background: Pancreatic ductal adenocarcinoma (PDAC), the most common cancer type in the pancreas, constitutes a major health problem worldwide beca...
The predictive value of BRCA mutation on survival of cancer patients treated with immune checkpoint inhibitors: A systematic review and meta-analysis of phase III randomized clinical trials.
2594 Background: Immune checkpoint inhibitors (ICIs) have significantly enhanced survival for various types of cancers; however, resistance has limited th...
Reflexed molecular testing to identify patients with biomarkers associated with tumor-agnostic FDA drug approvals.
e15160 Background: Advances in genomic technology and the development of an increased repertoire of targeted treatments are helping achieve better outcome...
Tislelizumab plus short-course chemo-radiotherapy for conversion therapy of unresectable ESCC (LATE): A proof-of-concept, phase Ib trial.
e16119 Background: The standard of care for unresectable locally advanced esophageal squamous cell carcinoma (ESCC) is definitive chemoradiation (dCRT). H...
Phase 1 dose-escalation trial of talazoparib in combination with belinostat in select advanced solid tumors.
3043 Background: Inhibitors of histone deacetylase (HDACi) may synergize with poly (ADP-ribose) polymerase inhibitors (PARPi). This Phase 1 dose escalatio...
Immunotherapeutic response score to predict prognosis for unresectable hepatocellular carcinoma with immune checkpoint inhibitors-based conversion treatment.
e16254 Background: Immune checkpoint inhibitor (ICI)-based conversion therapy is increasingly utilized for patients with initially unresectable hepatocell...
Longitudinal <i>EGFR</i> assessment in plasma and tissue samples in early non–small cell lung cancer (NSCLC).
8038 Background: Osimertinib has become the standard adjuvant treatment for patients (pts) with surgically resected, early-stage, EGFR...